ADARx Pharmaceuticals, Inc.
ADRXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Sep 2, 2026 | $-2.27 | — | $873.0K | — |
News
ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares Granted in Its Initial Public Offering
Prefer to listen? Hear this as a ~5-minute audio briefing on The GuruFocus Brief.Stock NewsKen Griffin donates $3B to Carnegie Mellon: Citadel CEO Ken Griffin p
ADARx Pharmaceuticals said on Thursday it had raised $446.3 million in an upsized US initial public offering, reflecting growing investor appetite for biotech listings.
SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today the pricing of its upsized initial public offering of 26,250,000 shares of common stock at a price to the public of $17.00 per share.